Summary. Genetic determination as well as prospective analysis of islet cell autoantibodies and autoantibodies to insulin were conducted in a population of 479 first degree relatives of 174 Type 1 (insulin-dependent) diabetic patients. Analysis of HLA haplotypes within families illustrated the high frequency of DR3 and DR4 alleles with preferential transmission from parent to both affected and unaffected offspring. DR4 was preferentially associated with DQw3.2 (TA10-) in 60/73 (82.2%) patients and 101/127 (79.5%) relatives. Relatives have been followed for a period of 800 subject-years. Twenty-two out of 430 relatives (5.1%) were found islet cell antibodies (ICA-IgG) positive. Seven sera with low titres became negative 6 months later at two different determinations. Fifteen sera ICA-IgG and ICA-protein A positive with high titres remained positive thereafter. Half of the ICA positive relatives were also found insulin autoantibodies (IAA) positive. All but 3 ICA negative relatives did not have IAA in their sera. Analysis of IAA specificity with competition experiments indicated that most antibodies recognised epitopes shared between human and pork insulins while four were specific for human insulin determinants. Analysis of class I and class II HLA antigen distribution indicated no particular allelic restriction in antibody positive individuals. Metabolic status of antibody positive relatives was determined with oral and intravenous charge of glucose. Two haplo-identical DR3-DQw2 brothers became diabetic during the study. One child and one mother both with DR4-DQw3.2 became intolerant to glucose. Each of these relatives had high titre ICA prior to metabolic deterioration. Taken together, these data indicated that ICA and IAA may be present in first degree relatives of diabetic patients. Individualisation of markers of the ongoing autoimmune process and accurate evaluation of the residual B-cell mass are necessary steps before further immune interventions in the early phases of the disease.
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A large number of data suggest that Type 1 (insulindependent) diabetes mellitus results from an autoimmune aggression of the B cells [1] . Specific class II histocompatibility complex antigens (DR3 and DR4) are associated with the disease [11, 17] . Recent studies have shown that clinical onset is preceeded by an asymptomatic period lasting from months to years characterised by the presence of circulating islet cell antibodies (ICA), insulin autoantibodies (IAA) prior to initiation of insulin treatment [7, 8] and an increased proportion of activated T lymphocytes [1] [2] [3] [4] [5] [6] . The frequency of organ-specific antibodies is highest near the time of diagnosis and falls progressively thereafter. The acute mode of onset would therefore result from a latent phase of B-cell destruction until the majority of insulin-secreting cells have been destroyed.
The present study was designed to evaluate the frequency of ICA and IAA in first degree relatives of patients with Type 1 diabetes and to determine the value of these autoantibodies as markers of ongoing autoimmunity and prediction of the disease. The polymorphism of IAA specificities and relationships of IAA with islet cell autoantibodies and HLA haplotypes have been also analysed and compared to the diabetic population.
Subjects and methods

Subjects
One hundred seventy-four Type I diabetic patients served as probands and fulfilled the following criteria for inclusion in our study [9] : (1)acute onset of insulin dependence and (2)ketone prone disease. Mean age at onset was 8.33 years (range: 2.9-20.8 years). Twenty-five patients were studied before administration of exogenous insulin.
A group of 524 first degree relatives was drawn from the ongoing prediabetes study of the clinic (1983 to date). This group was composed from 308 parents (age: 2%62, mean: 40.2 years), 209 siblings (age: 2-31.5, mean: 13.4 years) and 7 offspring (age 8-24.6, mean: 16 years). All relatives tested represented 174 unrelated families of Caucasian origin. In every family, two or more non-diabetic relatives were studied (mean number of 3) and 161 families had at least one unaffected child in addition to the one affected child. 430/524 (82%) relatives were tested at least once for the presence of specific autoantibodies (mean number of tests: 1.3) with a maximum of 5 tests. By the end of June 1988, the 430 relatives had been followed up for 800 subject-years until the time of their latest blood sample. All subjects were informed of the study and prior consent was obtained.
Fifty normal subjects, aged 2-16 years (mean: 11.8) served as control subjects of the immunological parameters. Two panels of 124 (panel A) and 192 (panel B) unrelated normal individuals from the local population served as control subjects for HLA antigen distribution.
Genetic studies
Our population was composed of 171 simplex and 3 multiplex families with more than one affected child. HLA antigens were analysed in 157/174 (90.2%) probands and in 479/524 (91.4%) relatives by standard microcytotoxicity methods for class I (A, B, C) and class II (DR, DQ) alleles. Panel A and panel B were used to determine the normal local distribution of class I and class II antigens respectively. DQw3 was split serologically with an anti-TA10 monoclonal antibody [10] . TAI0 expression correlates completely with DQ[~ restriction site polymorphism: DQw3/TA10 positive cells correspond to DQw3J and DQw3/TA10 negative cells to DQw3.2 [201.
The strength of HLA association was estimated using 2 x 2 contingency tables. The frequency of each allele in patients, its relative risk (RR), aetiologic fraction (EF) for positive associations (RR> 1) and preventive fraction (PF) for negative associations (RR < 1) were calculated with the appropriate formulas [11] 
Islet cell autoantibodies determination
Fasting blood samples were obtained from 430/524 relatives including 103 (24%) with more than one sample. Islet cell autoantibodies (ICA) were detected by indirect immunofluorescence as described by Bottazzo et al. [12] following the recommendations from the international committee for ICA standardisation [13] . Assays were performed on cryostat sections of a human pancreas of blood group O.
The majority of sera were tested on a single pancreatic tissue with a fluorescein conjugated sheep anti-human IgG antiserum (Wellcome reagents, Kent, UK) diluted 1:50. Only sera giving a positive signal at three different assays were regarded as positive. Antibodies detected by this conventional assay were referred to as ICA-IgG. Fluoresceinated protein A (protA-FITC) diluted 1:40 (Miles Laboratories, Paris, France) was used as a second step reagent to confirm the presence of specific antibodies. Interassay reproducibility was + one doubling dilution. In a group of 256 patients (mean age: 12 years, range: 2-35 years) within 4 months from clinical onset, 185 (72%) were found ICA-IgG positive with our assay. None of the fifty normal sera used as control reacted with pancreatic sections. ICA titres were converted into Juvenile Diabetes Fondation (JDF) units defined by a standard serum distributed for the Third International Workshop on ICA standardisation 1987 (obtained from C. Boitard, Paris, France). With the same pancreas and reagents, the JDF standard gave end point titres of 32 with the conventional method and of 16 with ProtA-FITC when tested at three different occasions. Ten JDF units were found equivalent to an ICA titre of 8.
Insulin autoantibodies determination
Sera from both ICA-positive and ICA-negative but genetically susceptible individuals were also tested for their ability to bind insulin with a modification of the fluid-phase quantitative radioassay described by Palmer et al. [7] . Eighty microlitres of serum were extracted with 50ul of Charcoal-l.5% Dextran T70 diluted in 0.04 mol/1 sodium phosphate buffer (pH 7.5) 0.5% bovine serum albumin (BSA) and 0.25% bovine gammaglobulins. Eighty microlitres from superuatant were incubated overnight in duplicate with a constant amount of radiolabelled pork insulin (sp.act. 203 to 250 ixCi/gg) (Biomrrieux, Lyon, France) or Tyr-A14 monoiodinated human insulin (sp.act. 200 to 270 ~xCi/p.g) (Novo Biolabs, Bagsvaerd, Denmark) in 140 ~tl of 0.04mol/1 phosphate buffer, 0.5% BSA and 0.25% bovine gammaglobulins. The amount of radiolabelled insulin added per tube was calculated according to the decay of radioactivity to obtain 60 pg of insulin. Antibody-bound radiolabelled insulin was precipited with 15% ice cold polyethylene glycol (tool. wt. 6000) prepared in 0.05 mol/1 veronal buffer with 0.25% BSA and 0.1% Tween 20. After centrifugation (2000 g, 30 mn, 4~ the resulting pellet was washed with 12.5% polyethylene glycol and centrifugated. Pellets were counted and results were expressed as the percentage of total radioactivity which could be precipitated. The mean binding of 50 non-diabetic control sera was 2.45 (range 1.6-4.7%) for pork insulin and 1.22 (range 0.6-2.2%) for human insulin. A positive result was defined as a value >3SD above the mean binding observed for normal sera. Consequently, sera with binding > 5% for pork insulin and > 2.5% for human insulin were considered as positive. For both assays the corresponding value exceeded the 99% upper confidence limit. Intra-assay coefficient of variation (CV) was 6% and inter-assay CV was 13%. In order to assess that the precipitating activity were immunoglobulins protein A from staphylococcus aureus cowan strain (Pansorbin, Calbiochem, La Jolla, Calif, USA) was used in some experiments. Results of the two methods 'were highly correlated (p <0.001, r=0.97). Diluting spontaneous anti-insulin antibodies and antibodies to exogenous insulin resulted in a decrease in binding values with comparable binding curves.
Absorption studies were carried out for each IAA positive serum using increasing concentrations of pork insulin (Organon Laboratories, St. Denis, France) or human insulin from recombinant origin (Lilly Laboratories, Indianapolis, Ind, USA) from 310-5~g to 3101 jxg insulin/ml of serum. For each IAA positive serum the amount of cold insulin which produced 50% inhibition (I50) of the maximum binding activity has been determined. Fourteen out of 25 newly diagnosed Type i diabetic patients were found IAA positive before treatment. Four of these IAA positive sera were specific for human insulin while the others recognised both pork and human insulins.
Metabolic studies
The metabolic status of antibody positive relatives was determined after an oral charge of 75 g of glucose (OGTT). According to the National Diabetes Data Group [9] , the diagnosis of diabetes was confirmed in subjects with either fasting blood glucose above 8 mmol/1 or glucose levels above 11 mmol/1 at more than one occasion during OGTT. Diagnosis of glucose intolerance was documented by a 8-11 mmol/1 plasma glucose value at 120 min. Insulin reserve was estimated I and 3 min after an intravenous infusion of 0.5 g/kg of glucose (IVGTT) in 2 min. Fifty-six normal subjects (mean age: 18.2 years, range: 7-27 years) with normal body weight served as control subjects for IVGTT. All subjects were fed a diet containing 250 g of carbohydrates 3 days before the test. The mean sum of insulinaemia 1 and 3 min following intravenous charge of glucose was 179.4 mU/l (range 80.9-341). The 95% lower confidence limit was 40 mU/1.
Statistical analysis
Rates of parent to offspring transmission were compared using a standard chi-square analysis for two-way classification. The repartition of the different autoantibodies were compared according to haplotypes, degree of HLA identity with the diabetic proband and immunological status. Comparisons between binding values of IAA and correlations between ICA titres and IAA levels were performed using linear regression analysis.
Results
HLA determination
As expected, HLA determination in first degree relatives indicated an increased rate in DR3 and DR4 al- haplo-identical (Table2). Out of 12 haplo-identical relatives with specific autoantibodies 8 (67%) shared DR4 with their diabetic proband whereas 3 (25%) shared DR3. Seven subjects initially weak ICA-IgG positive (mean titre: 1.2, range: 1-2) but ICA-ProtA negative were found ICA-IgG negative 6 months later at two different determinations on the same pancreas. Seven of the 15 ICA positive relatives (47%) had elevated IAA levels with a mean binding of 3.14 (range: 2.5 to 5.2%) for human insulin. Three out these 7 sera also bound pork insulin (mean: 7.16, range: 5.9 to 7.1%) whereas the 4 remaining sera were specific for human insulin determinants (mean: 3.2, range: 2.8 to 5%). Three out of 426 ICA-negative first degree relatives exceeded the normal binding range. Binding of autoantibodies to insulin was inhibited by preadsorption of sera with human or pork insulin depending on specificity (Fig.l) . The amount of non-radioactive human insulin which produced a 50% inhibition 05o) was 3 p.g/ml for a human insulin specific serum and 310 -2 lxg/ml for 3 non-human insulin-specific sera. Pork insulin did not modify the binding of the human specific IAA but inhibited the binding of non-human specific IAA (I50= 310 -3 ktg/ml). A pool of 12 diabetic sera containing natural antibodies toward exogenous insulin showed comparable I50 values for both insulins (0.3 gg/ml for human insulin and 0.2 gg/ml for pork insulin).
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No correlation was found between ICA titres and IAA levels in 12 newly diagnosed patients (r=0.08, p = 0.7) and 15 relatives (r = 0.03, p = 0.9) (Fig. 2) .
Characteristics of those relatives becoming diabetic or intolerant to glucose (Table 3)
Two out of the 7 ICA positive siblings became diabetic during follow-up. One was also IAA positive. Unfortunately, case l was detected a few weeks before onset of clinical disease. Two ICA and IAA positive relatives had impaired OGTFs and one had a reduced first phase insulin release during IVGTT on two occasions. All relatives were haplo-identical to the proband. Two of them expressed the DR4-DQw3.2 haplotype.
Discussion
We have determined in the present study the genetic patterns and the frequency of islet cell and insulin autoantibodies in first degree relatives of juvenile diabetic patients.
Humoral abnormalities may represent useful markers of ongoing autoimmunity that may lead to insulin deficiency as suggested by twin studies [3] and other prospective studies in first degree relatives of Type 1 diabetic patients [4] [5] [6] . The importance of autoimmunity in B-cell destruction has received further support from the observation that cyclosporine prolongs the remission of newly diagnosed diabetic patients [15] . Interest has been recently focused on factors assodated with a sustained remission under cyclosporine treatment. Preliminary conclusions suggest that immune intervention should be applied in the early stages of the disease in order to preserve the maximum amount of undamaged B cells [16] .
Probands included in the present study were comparable in terms of HLA class II patterns with patients from previous genetic studies with an increase in HLA DR3, DR4, DR3/4 and a decrease in DR2 [17, 18] . The rate of parent-to-offspring transmission of such high risk alleles was increased above 50%. We did not confirm a preferential transmission of DR4 from father origin, which has been proposed as an explanation for the increased risk of Type 1 diabetes observed in the offspring of men with the disease [19] . At present, determination of parental origin of DR3 or DR4 is of limited use in predicting those in whom Type 1 diabetes will develop. In fact, within families, risks of becoming diabetic depend more on the number of HLA haplotypes shared with the proband than with the presence of DR3 and/or DR4.
Although in linkage disequilibrium with separate diabetes susceptibility alleles, DR3 and DR4 are imperfect markers of Type 1 diabetes since they are found in 20 to 30% of the general population. Increasing evidence suggests that diabetes susceptibility alleles are located within the DQ region. DR4 is in strong linkage disequilibrium with DQw3 in Caucasians. Analysis of DQw3 fragments in our population revealed an increased proportion of DR4-DQw3.2 (TA10-) haplotypes both in probands and relatives. The DQ[3 chain that encodes for DQw3.2 (TA10-) antigen does not have an Aspartate in position 57. This has been recently reported as a hallmark of Type 1 diabetes [21] . DNA sequencing of DQ[3 genes may indeed provide further understanding of the genetic susceptibility for the disease.
Two ICA-positive subjects progressed to diabetes within one year. Two other ICA-positive relatives were found intolerant to an oral charge of glucose. Islet cell autoantibodies may therefore be considered as useful markers of ongoing autoimmunity. However, ICA titre has to be taken into consideration. Indeed, all of the 7 sera initially weak positive became negative thereafter on two different occasions. On the other hand, ICA positive sera with high titres remained positive at 3 different occasions within 3 years. The fact that ICA may fluctuate has already been a matter of controversy [14] . It is not known whether this fluctuation results from the poor sensibility of antibody detection, or reflects fluctuations in the destruction process with transient B-cell recovery. In the present study, all ICA-positive subjects have been retested with frozen sections from the same pancreas both with conventional ICA assay and protein A-FITC assay.
Autoantibodies directed toward the insulin molecule have been recently individualised in newly-diagnosed diabetic patients by Palmer et al. [7] . Studies by Wilkin et al. [8] and Dean et al. [22] in first degree relatives suggested that such antibodies could be associated with the development of autoimmunity toward B cells. In our study, IAA were found more frequently in ICA positive individuals. Data on IAA determinations are difficult to interpret due in part to the lack of standardisation between radioimmunoassay and immunoenzymatic techniques. The latter gains in sensitivity, but not in specificity since 8% of normal individuals have been found antibody positive with this technique [21] . Radio-immunoassay techniques increase the threshold for IAA positivity and consequently may better reflect an active destruction process. This underlines the need for standardisation to determine the utility of each assay format [26] . As have others [23] , we report an inverse relationship between age and IAA levels. It remains to be elucidated whether this reflects an heterogeneity in the duration of B-cell destruction or in the mechanisms leading to B-cell failure. ICA positive relatives showed limited fluctuation in IAA levels during follow-up, and most of the observed fluctuations were in the range of our inter-assay variation.
The mechanisms by which IAA could occur in newly diagnosed Type 1 diabetic individuals and in healthy relatives are still a matter of speculation. Immunological destruction of B cells may be responsible for an abnormal presentation of insulin determinants to the immune system but may also be relevant from the inbalance of an idiotype anti-idiotype network centered on insulin and its receptor [25] .
More than a hundred different epitopes have been mapped on the insulin molecule using monoclonal antibodies. An heterogeneity of the antigenic repertoire of IAA in newly diagnosed diabetic patients has been reported by Diaz et al. [27] . Some autoantibodies recognised both pork and human epitopes while others were specific for human determinants only. In the present study, we provide evidence for an heterogeneity of antibody repertoire both in untreated patients and in relatives. Although the majority of IAA found in the sera of relatives were non-human specific, an important goal will be to evaluate whether epitope restriction and species specificity need to be taken into consideration for the predictive value of these autoantibodies. This dual binding pattern was never observed with antibodies against exogenous insulin which were cross-reactive independently from the type of insulin chosen for treatment.
Various autoimmune markers have been associated with Type 1 diabetes [28] and some have been studied in first degree relatives with the hope that an array of serological markers will increase the quality of prediction. However, both experimental and clinical studies suggest that cellular components from the immune system are the effectors of B-cell destruction. The lack of specific peripheral cellular markers due in part to the absence of characterisation of the target antigen is an important limiting factor for large scale prospective analysis. Moreover, the presence of specific autoantibodies in genetically susceptible individuals does not necessarily reflect the course of B-cell damage leading to clinical presentation. In some relatives, islet cell autoantibodies with impaired insulin secretion may precede for months the onset of the disease while other ICA positive relatives do not progress to diabetes.
In conclusion, ICA and IAA are clearly the major indicators of ongoing immunity toward B cells in genetically susceptible individuals. Some parameters including antibody specificity may be more closely associated with active B-cell damage. However, it remains difficult to evaluate the number of residual functional B cells and therefore to predict insulin deficiency. The variable outcome of relatives with autoimmune markers may also reflect an heterogeneity in the disease process. Further peripheral markers of the immune process that lead to B-cell destruction and accurate evaluation of B-cell reserve are clearly necessary in the future considering specific immune interventions that may limit B-Cell damage.
